Kenya’s National newspaper reported on February 19 that the Kenyan Pharmaceutical and Poisons Authority officially approved the country’s use of the coronavirus vaccine developed by AstraZeneca Pharmaceutical Company and Oxford University, paving the way for vaccination activities in the coming weeks.
South Africa, which first began to use the AstraZeneca coronavirus vaccine, said on the 7th of this month that it had decided to stop using the vaccine.
Because studies have shown that two doses of AstraZeneca coronavirus vaccine provide only “minimum protection” for mild and moderate infections for mutant coronaviruses found in South Africa.
The Ken administration plans to vaccinate about 15.91 million people in three of its citizens against the coronavirus in 18 months.
